Agios Pharmaceuticals Stock Rises on FDA Priority Review for Mitapivat in Sickle Cell Disease
Shares of Agios Pharmaceuticals (NASDAQ: AGIO) surged over 14% after the FDA accepted its supplemental New Drug Application for mitapivat to treat sickle cell disease with a Priority Review, setting an action date by November 1. Although the drug missed one primary endpoint in clinical trials, the decision signals regulatory confidence.
Topics: drug approval mitapivat pharmaceutical sickle cell disease